Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenylpyridine class of organic compounds. It features a pyrazolo[3,4-b]pyridine core with a morpholine and methanamine substituent. The drug is experimental and has not been approved for any indication. Its primary known biological target is serine/threonine-protein kinase Chk1 (Checkpoint kinase 1), which plays a key role in cell cycle regulation and DNA damage response. Inhibition of Chk1 can sensitize tumor cells to DNA-damaging agents by abrogating cell cycle checkpoints, making this compound of interest as an anticancer agent in preclinical research settings[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine.